An international research-based pharmaceutical company, specializing in products for the treatment of gastroenterological, cardiovascular and central nervous system diseases.
Dexcel Pharma is the fourth-largest Israeli pharmaceutical manufacturer, ranked by sales volume. The company has subsidiaries in the USA, the UK and Germany, and has over 1,000 employees worldwide. Approximately 85% of the company’s production is exported to international markets.
As a dominant part of the Israeli pharmaceutical industry, Dexcel Pharma enjoys the advantages generated by the Israeli occupation of Palestinian lands, allowing the company to exploit the Palestinian market. ‘Quality and Security reasons’ in conjunction with economic and political justifications create a Palestinian captive market for Israeli and multinational companies.
The Paris Protocol, an annex to the Oslo Accords, which regulates the financial relations between Israel and the future Palestinian state, placed both entities under the same taxation envelope. As a result, the Palestinians continue to depend on Israeli policies, customs laws and services for the import and export of goods. This dependency has inflicted strong negative economic effects on the Palestinian pharmaceutical industry. Various hindrances generate extra costs that harm the development of the local industry: the burden of the annual licensing of imported raw materials, the costs of back-to-back deliveries to and from the West Bank and the Gaza Strip, the costs of shipping drugs in bulk via Jordan, the exclusion of large Arab markets as well as in Israel, and the inability of the Gazan industry to develop and expand due to the prohibition on export.
Dexcel Pharma, like other Israeli and multinational companies, enjoys the aforementioned situation in several ways. The company enjoys easy access to the Palestinian market, free of customs and checkpoint, e.g. change of trucks at cargo checkpoints. Dexcel Pharma’s agents do not have to amend any of their products in order to sell them in the oPt. Thus, the company can sell drugs that are not labeled in Arabic. Dexcel Pharma meets little to no competition from the cheaper generic drug industry, as a result of the Israeli Ministry of Health restrictions on drug registration in Israel and their enforcement on the Palestinian market.
For further information, check our report on the Pharmaceutical Industry: Captive economy.
The company is fully owned by its founder and CEO Dan Oren.
Dexcel Pharma Technologies (USA), Dexcel Pharma (Germany), Dexcel-Pharma (UK)
All the information contained in this page is valid until Sun 22/07/2012
- Altice International
- B Communications
- B. Gaon Holdings
- B.D.T.H Israel Solar Energy Ltd.
- Baran Group
- Bezeq – The Israeli Telecommunication Corporation
- CETCO Mineral Technology Group
- Cisco systems
- Gadish Engineering – Yoram Gadish Group
- Hot Mobile (formerly: Mirs Communications)
- Maman Cargo Terminals and Handling
- Paz Oil Company
- Pelephone Communications
- Peretz Bonei Hanegev
- Salomon, Levin & Elstein (SLE)